Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Zhengxiong Li
Institution:
Xuzhou Medical College
Observed institutions:
Xuzhou Medical College,
Chinese PLA General Hospital,
Chinese People's Liberation Army,
Southern Medical University
ORCID:
0009-0000-6031-4755
Observed ORCID:
0009-0000-6031-4755
OpenAlex ID:
A5067330443
Long non-coding RNA FTH1P3 promotes the metastasis and aggressiveness of non-small cell lung carcinoma by inducing epithelial-mesenchymal transition.
2019
·
Zhengxiong Li
, Yadi Wang
·
Europe PMC (PubMed Central)
·
10
Cost-effectiveness analysis of anlotinib plus penpulimab versus sorafenib in the treatment of unresectable hepatocellular carcinoma
2025
·
Jiefeng Luo
, Zhengxiong Li
, et al.
·
Human Vaccines & Immunotherapeutics
·
7
Cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib plus fulvestrant as first-line treatment in HR+/HER2-advanced breast cancer
2026
·
Jiaming Zhu
, Ye Ding
, et al.
·
The Breast
·
6
PDF
Ramucirumab plus paclitaxel as switch maintenance in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer: a cost-effectiveness analysis
2025
·
Jiefeng Luo
, Zhengxiong Li
, et al.
·
Frontiers in Pharmacology
·
5
Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for extensive-stage small cell lung cancer in China
2025
·
Xiongxiong Fan
, Zhengxiong Li
, et al.
·
Frontiers in Public Health
·
3
PDF
Cost-effectiveness of sugemalimab plus chemotherapy as first-line therapy in advanced gastric cancer and gastroesophageal junction cancer.
2025
·
Jiaming Zhu
, Zhengxiong Li
, et al.
·
Annals of Medicine
·
2
PDF
Cost-effectiveness of talazoparib plus enzalutamide as first-line therapy in metastatic castration-resistant prostate cancer
2025
·
Jiaming Zhu
, Zhengxiong Li
, et al.
·
Therapeutic Advances in Medical Oncology
·
2
First-line sugemalimab plus chemotherapy for metastatic non-small-cell lung cancer: an updated cost-effectiveness analysis based on 4-year survival data
2026
·
Zhengxiong Li
, Jiaming Zhu
, et al.
·
Expert Review of Pharmacoeconomics & Outcomes Research
Exploring the optimal regimen in advanced hepatocellular carcinoma: a protocol of individual patient data network meta-analysis of randomized controlled trials
2026
·
Jiefeng Luo
, Zhengxiong Li
, et al.
·
Frontiers in Immunology
PDF
Show more works
View as search
Works count:
9
Citation count:
35
H-index:
4
I10-index:
1
Year
Topic
Type